Sovereign nonsense: Patent board joins the lineup of critics dissing Allergan's 'illusory' IP deal with the Mohawks
Allergan’s $AGN attempt to make an end run around an inter partes review of its patents for its blockbuster Restasis franchise has been dissed by a federal judge, ridiculed by a US Senator and now tossed out by the Patent Trial and Appeal Board.
Handing over the patents to a Mohawk tribe, which then declared that IPR could not apply to a group with sovereign immunity, swiftly boiled up into a controversy in which Allergan’s Brent Saunders stoutly defended the legitimacy of the deal. And Allergan handed over close to $14 million in cash to get it rolling, with quarterly payments totaling $15 million a year to keep it going.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.